000046369 000__ 01098cam\a22004095i\4500
000046369 001__ 46369
000046369 003__ SzGeWIPO
000046369 005__ 20240708150240.0
000046369 006__ m\\\\eo\\d\\\\\\\\
000046369 007__ cr bn |||m|||a
000046369 008__ 220616s2020\\\\nyu\\\\\o\\\\\000\0\eng\d
000046369 035__ $$a(OCoLC)1335038954
000046369 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046369 041__ $$aeng
000046369 24500 $$aSupreme Court's approach to obviousness applied: Allergan v Aspire.
000046369 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2020
000046369 300__ $$a1 online resource
000046369 336__ $$atext$$2rdacontent
000046369 337__ $$acomputer$$2rdamedia
000046369 338__ $$aonline resource$$bcr$$2rdacarrier
000046369 4901_ $$aEuropean Intellectual Property Review,$$x0142-0461 ;$$vVolume 42, Issue 1
000046369 542__ $$fhttps://1.next.westlaw.com/Copyright
000046369 588__ $$aCrossref
000046369 590__ $$aPublished online: 2020
000046369 650_0 $$aIntellectual property.
000046369 650_0 $$aHealth.
000046369 650_4 $$aPrior art (Patent law)
000046369 650_4 $$aPharmaceuticals
000046369 7001_ $$aFischer, Nicholas,$$eauthor.
000046369 7001_ $$aHutchinson, Andrew,$$eauthor.
000046369 7731_ $$tEuropean Intellectual Property Review
000046369 7731_ $$wEIPR
000046369 830_0 $$aEuropean Intellectual Property Review,$$vE.I.P.R. 2020, 42(1), 69-73
000046369 85641 $$uhttps://www.westlaw.com/Document/I340D3430130B11EA9A0CA1AADEC7D863/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046369 904__ $$aJournal article
000046369 980__ $$aEIPR